The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival-Reference-Cited by-同舟云学术

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival

Published:2019-11-19 Issue:2 Volume:95 Page:144-150
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Yilmaz Musa¹^ORCID,Kantarjian Hagop¹^ORCID,Wang Xuemei²,Khoury Joseph D.³^ORCID,Ravandi Farhad¹,Jorgensen Jeffrey³,Short Nicholas J.¹^ORCID,Loghavi Sanam³,Cortes Jorge¹^ORCID,Garcia‐Manero Guillermo¹,Kadia Tapan¹^ORCID,Sasaki Koji¹,Konopleva Marina¹,Takahashi Koichi¹,Wierda William¹,Jain Nitin¹,Verstovsek Srdan¹,Estrov Zeev¹,Bose Prithviraj¹^ORCID,Pierce Sherry¹,Garris Rebecca¹,O'Brien Susan⁴^ORCID,Jabbour Elias¹^ORCID

Affiliation:

1. Department of LeukemiaThe University of Texas MD Anderson Cancer Center Houston Texas

2. Department of BiostatisticsThe University of Texas MD Anderson Cancer Center Houston Texas

3. Department of HematopathologyThe University of Texas MD Anderson Cancer Center Houston Texas

4. Chao Family Comprehensive Cancer CenterUniversity of California Irvine Orange California

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25671

Reference25 articles.

1. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia

2. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

3. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

4. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

5. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy;The Korean Journal of Internal Medicine;2024-01-01

2. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-12

3. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past;The Lancet Haematology;2023-05

4. Minimal Residual Disease in the Management of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review of Studies from Indian Settings;Indian Journal of Hematology and Blood Transfusion;2023-03-30

5. CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study;Blood Cancer Journal;2023-03-24